← Leaderboards
Nikesha Gilmore
University Of Rochester
$505,296
Attributed
$505,296
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $168.5K · FY2023–25$200K$150K$100K$50K$0
'23
'24
'25
Funding mix
By agency
NIH$505,296 · 1
By mechanism
K01$505,296 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Rochester
Same institution · by research overlap
- Annalynn Williams$1,148,708
- Denise C Hocking$8,102,756
- Diane Dalecki$5,730,400
- Gary R Morrow$66,207,520
- Thomas A Gasiewicz$24,015,628
Others in their field
Other Rising Stars on “Development Plans”
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Mari Ostendorf · University Of Washington$51,931,230
- Richard Smith · Medical Device Innovation Consortium$41,401,350
- Maximilian Haeussler · University Of California Santa Cruz$12,592,563
- Joon Sup Lee · Emory University$10,751,414
- Meera Sampath · Suny At Binghamton$9,956,488
Research focus
Development PlansDoseClinical TrialsDesignAdverse EventDna MethylationCatechinClinical Trial ParticipantAnxietyAscorbic AcidBasic ScienceBehavior TherapyBiologicalBiological MarkersBiometryAdherenceAnti-Inflammatory AgentsClinical ResearchCancer ControlCancer SurvivorCancer TherapyCapsuleCareer DevelopmentElderly
Grant awards (3)
A Phase II Randomized Placebo Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Physical Frailty and Tumor Necrosis Factor-alpha and Associated Immune Markers in Older Cancer Survivors$168,496
K01 · FY2025 · CA · contact PI
A Phase II Randomized Placebo Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Physical Frailty and Tumor Necrosis Factor-alpha and Associated Immune Markers in Older Cancer Survivors$168,496
K01 · FY2024 · CA · contact PI
A Phase II Randomized Placebo Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Physical Frailty and Tumor Necrosis Factor-alpha and Associated Immune Markers in Older Cancer Survivors$168,304
K01 · FY2023 · CA · contact PI